2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Polycystic Ovary Syndrome
9
Hyperandrogenism
4
Neoplasms
3
Inflammation
2
Heart Failure
2
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Skin Diseases
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Sarcoma
1
Retinitis
1
Renal Insufficiency, Chronic
1
Rare Diseases
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Obesity
1
Neutropenia
1
Migraine Disorders
1
Metabolic Syndrome
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Interventions
Echocardiography
4
sacubitril and valsartan sodium hydrate drug combination
3
Standard of Care
3
Nutrition Assessment
3
Exercise
3
Electrocardiography
3
Carvedilol
3
dapagliflozin
2
Surveys and Questionnaires
2
Spironolactone
2
Rituximab
2
Lenalidomide
2
Ivabradine
2
Control Groups
2
Blood Specimen Collection
2
Atorvastatin
2
Adrenergic beta-Antagonists
2
ziprasidone
1
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Zolpidem
1
Watchful Waiting
1
Warfarin
1
Vincristine
1
Vecuronium Bromide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Heart Failure
×
Spironolactone
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled